Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Semler Scientific Names Wayne T. Pan, M.D., Ph.D., M.B.A. as New CEO
Semler Scientific, a company that provides technology solutions to improve the clinical effectiveness and efficiency […]
Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that […]
Gamida Cell Announces Changes to Board of Directors
Gamida Cell, a cell therapy pioneer working to turn cells into powerful therapeutics, today announced […]
GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman
Gemini BioProducts (GeminiBio), a portfolio company of BelHealth Investment Partners, a Florida-based healthcare private equity […]
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors
Vanda Pharmaceuticals today announced the appointment of Dr Tage Honoré, Ph.D., D.Sc. to its Board […]
Sage Therapeutics Appoints Jessica Federer to Board of Directors
Sage Therapeutics, a biopharmaceutical company leading the way to create a world with better brain […]
Diamyd Medical brings Karin Rosén, M.D, PhD, to its Board of Directors
Diamyd Medical today announced that Karin Rosén will join the Board of Directors as an […]
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to […]
Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman
Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with […]
Artax Biopharma Appoints Andre Hoekema, Ph.D., to Company's Board of Directors
Artax Biopharma, a clinical-stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more